MedTrace Logo

Double-blind Comparative Study of SYR-472

NCT01632007 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2023-12-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Conditions

Interventions

DRUG

SYR-472

DRUG

Alogliptin 25 mg

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)

Study Design

Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-01
Primary Completion
2013-07-01
Completion
2013-07-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632007 on ClinicalTrials.gov